Earnings ·
Longeveron Inc. reported financial and operating results for the three and six months ended June 30, 2026
LGVNLongeveron Inc.
Longeveron Inc. reported financial and operating results for the three and six months ended June 30, 2026. The company incurred a net loss of $6.1 million for the quarter, compared to $5.0 million in the prior year period. Revenues remained flat at $0.3 million, driven by clinical trial revenue as contract manufacturing revenue ceased. Cash and cash equivalents stood at $10.1 million as of June 30, 2026, with management anticipating this runway will extend into the fourth quarter of 2026. The company is approaching top-line results from its Phase 2b ELPIS II clinical trial for laromestrocel in hypoplastic left heart syndrome, expected in September 2026. Additionally, Longeveron was selected as a finalist and received a $1.0 million Milestone 2 Award from the XPRIZE Healthspan competition. The company operates in the biotechnology industry, developing cellular therapies for rare pediatric and chronic aging-related conditions.